SOURCE: AVI BioPharma, Inc.

May 08, 2008 09:30 ET

AVI BioPharma Announces First Quarter 2008 Financial Results Conference Call

PORTLAND, OR--(Marketwire - May 8, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII) today announced that the company will hold a conference call to report its first quarter 2008 financial results on Tuesday, May 13, 2008, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing 866.507.1212 toll free within the United States and Canada, or 416.695.7848 for international callers.

Following the conference call, a recording of the call will be available for download (MP3) on the company's website:

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NeuGene® antisense drugs and ESPRIT directed RNA alternative splicing technology. AVI's ESPRIT technology is initially being applied to potential treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds are also designed to treat cardiovascular restenosis in stent and coronary artery bypass graft (CABG) procedures. In addition to targeting specific genes in the body, AVI's antiviral program uses NeuGene antisense compounds to combat disease by targeting single-stranded RNA viruses, including Marburg Musoke and Ebola Zaire viruses. More information about AVI is available at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Contact Information

  • AVI Press and Investor Contact:
    Michael Hubbard
    Email Contact
    Director of Corporate Communications
    (503) 227-0554